- Obama asks the Senate to ratify the Marrakesh treaty for the blind
- USPTO White Paper Suggests Statutory Factors To Clarify Extent of Statutory Damages for Copyright Infringement
- NIH acknowledges KEI/UACT request to use royalty-free or march-in rights on Xtandi
- Feasibility study on a TDR pooled fund for R&D to be released on 20 February 2016
- SAVE THE DATE - 26 January 2016: Implications of the TPP and RCEP on Universal Health Coverage
- Xtandi 2016 March-In Request
- Knowledge Ecology International joins amicus brief on non-copyrightability of model laws and statutes
- 51 members of Congress have asked the NIH to use March-In rights to rein in high drug prices
- WHO's evaluation of the global strategy and plan of action on public health, innovation and intellectual property
- FDA approves 45 new drugs. 47 percent qualify for 50 percent Orphan Drug tax credit
Today, Tibotec, a subsidiary of Johnson & Johnson, announced it has signed voluntary licensing agreements with several Indian and South African generic companies to allow generic competition on a new HIV-AIDS treatment, the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278) (rilpivirine hydrochloride), to certain developing countries.
The following is an article by Agathe Duparc which appeared on page four of the Sunday/Monday edition (23 January-24 January 2011) of Le Monde with a reference on the cover page. Below the article are two paragraphs providing readers with more background information on the World Health Assembly and the Executive Board. The third paragraph is the main quote highlighted in the print version. What is missing in this copy below is a cartoon accompanying the piece which shows a bespectacled man with a body of an octopus holding two syringes in a field of dollar signs.
After several days of negotiations, the 128th WHO Executive Board has accepted the nomination of Paul Herrling to the new WHO Consultative Expert Working Group on R&D Financing, despite the fact that Herrling is an executive of Novartis, and is the author of the IFPMA/Novartis/FRIND proposal and the co-author of the PDP Plus proposal, which will be considered by the CEWG.
Nine civil society groups write WHO Executive Board about conflict of interest on WHO R&D Financing groupSubmitted by KEI Staff on 20. January 2011 - 10:33
On January 20, 2011, 9 civil society organizations sent a letter to the WHO Executive Board registering an objection to the selection of Dr. Paul Herrling of Novartis to the WHO Consultative Expert Working Group on Research and Development: Financing and Coordination. The groups signing the letter were:
- Déclaration de Berne - Berne Declaration
- HAI Europe
- HAI Global
- Health GAP (Global Access Project)
WHO has kindly made available its conflict of interest guidelines. Apparently they are not available from the public web page. Attached are two documents:
A few of the many interesting provisions follow:
I. MEANING OF "CONFLICT OF INTEREST"
On Tuesday the 18th of January 2010,German Green MEP Franziska Keller tabled this Parliamentary question:
European members of WHO Executive Board take hard line on nomination of Novartis official to R&D groupSubmitted by thiru on 19. January 2011 - 7:38
At the 128th meeting of the WHO Executive Board (EB), the European members of the board are reportedly taking a hard line on the proposal by Switzerland to have Paul Herrling, an executive of Novartis, appointed to the WHO Consultative Expert Working Group (CEWG) on R&D financing. Our earlier blogs on this controversy are available here and here).
US government urges WHO to support Medicines Patent Pool: Extract of US intervention on draft WHO HIV/AIDS strategy 2011–2015Submitted by thiru on 18. January 2011 - 12:53
On Tuesday's discussion at the 128th Executive Board on the Draft WHO HIV/AIDS strategy 2011–2015, the United States made a strong intervention (delivered by Dr. Nils Daulaire, Director, Office of Global Health Affairs, Department of Health and Human Services) in support of the Medicines Patent Pool drawing attention to the fact that the draft HIV/AIDS strategy while making reference to a more competitive market for ARVs, failed to recognized the importance of the Medicines Patent Pool.
Here below are the remarks of the US on this point:
Conflicts of Interest, and the WHO evaluation of the FRIND and the PDP Plus funding proposals by the CEWGSubmitted by thiru on 18. January 2011 - 11:19
This note provide additional context for those who are just now following the issue of conflicts of interest and the WHO Consultative Expert Working Group (CEWG) on R&D Financing.
The CEWG follows a controversial, flawed and failed effort by an earlier group, the WHO Expert Working Group (EWG) on R&D Financing, to:
At the end of the day on Monday, the 128 WHO Executive Board meeting took the agenda item for creation of a new R&D Financing consultative expert working group (CEWG). (Yesterday's blog on this topic is here)
World Health Organization Executive Board to create new consultative expert working group on R&D FinancingSubmitted by James Love on 17. January 2011 - 8:55
Today the WHO is expected to take up the Report by the Secretariat on "the Establishment of a consultative expert working group on research and development: financing and coordination." (link here).
The following reports the number of Google hits using the search term "gates foundation," with a site:domainname option, on January 7, 2011. The result is a count of the number of web pages (visible to Google) mentioning the Gates Foundation on a particular domain.
For example, the google search site:who.int "gates foundation" identified 5,940 pages on the who.int web site that have the exact phrase, "gates foundation."
Google hits for "health messages embedded in television" 275,000
Motivating Television Viewers to Become Organ Donors
Authors: Lauren Movius, Michael Cody, Grace Huang, Mandy Berkowitz, Susan Morgan
Corresponding Author: Lauren Movius, Annenberg School of Communication, University of Southern California, email@example.com.
On December 14, 2010, Life Technologies Corporation, which among other things owns Ion Torrent, which sells the Ion Personal Genome Machine sequencer, announced seven new medical innovation prizes. The first three prizes are related to improvements in the Ion semiconcudtor sequencing products. Each of the three sequencer prizes is funded at $1 million, and will be awarded to contestants that can achieve the following goals:
- produce twice as much sequence data,